United Therapeutics
UTHR
385 hedge funds and large institutions have $5.25B invested in United Therapeutics in 2016 Q2 according to their latest regulatory filings, with 43 funds opening new positions, 152 increasing their positions, 140 reducing their positions, and 52 closing their positions.
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
9% more repeat investments, than reductions
Existing positions increased: 152 | Existing positions reduced: 140
2% less call options, than puts
Call options by funds: $29.2M | Put options by funds: $29.9M
4% less funds holding
Funds holding: 399 → 385 (-14)
8% less capital invested
Capital invested by funds: $5.67B → $5.25B (-$426M)
17% less first-time investments, than exits
New positions opened: 43 | Existing positions closed: 52
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
CCM
Consonance Capital Management
New York
|
+$46.7M |
| 2 |
TSW
Thompson Siegel & Walmsley
Richmond,
Virginia
|
+$37M |
| 3 |
AQR Capital Management
Greenwich,
Connecticut
|
+$30.9M |
| 4 |
AL
AJO LP
Philadelphia,
Pennsylvania
|
+$28.9M |
| 5 |
AI
Analytic Investors
Los Angeles,
California
|
+$23.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
-$64.1M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
-$42.7M |
| 3 |
BA
BlackRock Advisors
Wilmington,
Delaware
|
-$28.7M |
| 4 |
BIM
BlackRock Investment Management
Wilmington,
Delaware
|
-$27.4M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$25.8M |
UTHR Hedge Fund Activity: Q2 2016 in Review
385 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in United Therapeutics (UTHR) for Q2 2016, worth a combined $5.25B — down 7.5% from $5.67B a quarter earlier.
Sellers outnumbered buyers: 52 funds closed out of UTHR and 43 opened new positions — a net loss of 9 holders — while 140 trimmed existing stakes and 152 added.
The largest buyer was Consonance Capital Management, opening a new position worth an estimated $46.7M. The largest seller was Invesco, cutting an estimated $64.1M.
- 385 institutional investors held United Therapeutics (UTHR) as of Q2 2016, down from 399 in Q1 2016.
- Funds reported $5.25B of United Therapeutics stock for Q2 2016, down 7.5% quarter-over-quarter.
- 43 funds opened new United Therapeutics positions in Q2 2016 and 52 closed out, a net change of -9 holders.
- The largest United Therapeutics buyer in Q2 2016 was Consonance Capital Management, an estimated $46.7M added.
- The largest United Therapeutics seller in Q2 2016 was Invesco, an estimated $64.1M sold.
Based on aggregated 13F filings for Q2 2016.